Premium
P4‐417: The effects of statin use on Alzheimer's disease CSF biomarkers in cognitively healthy elderly
Author(s) -
Glodzik Lidia,
Bikhazi Vanessa
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.09.113
Subject(s) - medicine , statin , cohort , apolipoprotein e , cerebrospinal fluid , disease , biomarker , lumbar puncture , oncology , biochemistry , chemistry
a speeded dexterity task and plasma isoflavone levels. Conclusions: Six months of 100mg/day treatment with soy isoflavones did not benefit cognition in older men and women with Alzheimer’s disease. However, given the variability in older adults’ ability to metabolize and absorb oral forms of isoflavones, we examined the association between changes in plasma levels of total isoflavones and changes in cognition. While preliminary, these data suggest the possibility of a dose response effect, such that only individuals able to convert aglycone forms of isoflavones to the glycosidic metabolites have the potential to demonstrate cognitive effects.